Nasus Pharma (NSRX) Total Current Liabilities (2024 - 2025)
Nasus Pharma's (NSRX) quarterly Total Current Liabilities came in at $2.2 million in Q4 2025, down 44.95% YoY from $3.9 million in Q4 2024, and down 56.33% on a QoQ basis from $5.0 million in Q2 2025.
Nasus Pharma (NSRX) Total Current Liabilities (2024 - 2025) Analysis & Trends
Nasus Pharma (NSRX) has 2 years of Total Current Liabilities data on file, last reported at $2.2 million in Q4 2025.
- Quarterly Total Current Liabilities fell 44.95% year-over-year to $2.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.2 million (down 44.95% YoY) and the FY2025 annual result came in at $2.2 million, down 44.95% from the prior year.
- Total Current Liabilities retreated to $2.2 million in Q4 2025, from $5.0 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $5.0 million in Q2 2025 to a low of $2.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.85 Bn | 633.09 Bn | 17.26 Bn | 54.90 Bn |
| 2 | AbbVie | 471.53 Bn | 464.96 Bn | 12.70 Bn | 41.64 Bn |
| 3 | Merck | 380.02 Bn | 372.88 Bn | 12.21 Bn | 27.73 Bn |
| 4 | Novartis Ag | 303.58 Bn | 295.89 Bn | 11.24 Bn | 31.75 Bn |
| 5 | Astrazeneca | 258.47 Bn | 253.57 Bn | 12.86 Bn | 31.55 Bn |
| 6 | Amgen | 237.24 Bn | 223.25 Bn | 7.24 Bn | 25.50 Bn |
| 7 | Gilead Sciences | 183.09 Bn | 179.91 Bn | 6.22 Bn | 11.02 Bn |
| 8 | Pfizer | 161.82 Bn | 150.12 Bn | 10.94 Bn | 32.65 Bn |
| 9 | Gsk | 105.93 Bn | 101.77 Bn | 8.24 Bn | -28.89 Bn |
| 10 | Nasus Pharma | 29.73 Mn | 29.73 Mn | - | 2.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.16 Mn |
| Jun 30, 2025 | 4.95 Mn |
| Dec 31, 2024 | 3.93 Mn |